Expert consensus on clinical trials of disease-modifying agents in pediatric multiple sclerosis

Lire cet article en français

Takeaway

  • Experts underline the need for high-quality evidence-based treatment for pediatrics with multiple sclerosis (MS), with a focus on the safety and efficacy of disease-modifying therapies (DMT).

Why this matters

  • Given the similarity in the biology of MS between adults and children, there is a rationale for using MS treatments with proven efficacy in adults in pediatric MS; experts highlight the need for updated consensus regarding clinical trials in the pediatric population.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.